Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — Mounjaro's KwikPen is not designed to deliver a partial dose, and splitting or adjusting the amount you inject is not a supported or safe practice. Each pre-filled pen dispenses a fixed quantity of tirzepatide in a single press; there is no mechanism to dial down the volume. If side effects are making a full dose difficult to tolerate, the right move is a conversation with your prescriber, not improvising with the pen. These are prescription-only medicines, and how much you take is decided through clinical assessment, not trial and error at home.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The KwikPen works by releasing the entire contents of a single-dose cartridge in one automatic press. There is no adjustable window, no graduated scale, no way to stop delivery mid-injection. The pen is engineered this way deliberately, precision matters when you're dealing with a medicine dosed in milligrams. Once you press the button, the full amount goes in.
This is worth spelling out because a common misconception circulates online: that you can hold the pen partway, or press it lightly, to get a smaller amount. You cannot. The mechanism doesn't work like that. The dose is fixed at manufacture, and the pen's job is to deliver all of it reliably, every time.
For a thorough overview of how tirzepatide works as a dual GIP and GLP-1 receptor agonist, the Mounjaro guide on our treatment pages covers the mechanism in plain terms. The NHS also publishes patient-level information on tirzepatide at nhs.uk/medicines/tirzepatide, including how the medicine is given.
The desire to take less is usually driven by side effects: nausea, an unsettled stomach, or just feeling that the current dose is more than your system wants right now. That instinct makes sense. But the licensed schedule already accounts for this.
Mounjaro starts at 2.5mg, a strength that exists purely to let your body settle in before anything changes. It is not a therapeutic dose in the sense of delivering maximum weight-loss effect; its job is adjustment. If 2.5mg is causing significant discomfort, the answer isn't to attempt a smaller injection. It is to discuss with your prescriber whether staying at 2.5mg for longer is appropriate, or whether something else is contributing to the symptoms.
When a planned dose increase is proving difficult to tolerate, clinical guidance supports pausing at the current strength rather than moving up. That is a legitimate, clinically supported strategy. People sometimes wonder whether taking half a dose of Mounjaro is possible, but trying to extract half a dose from a pen that isn't built for it is not. Questions about doubling doses follow a similar logic from the other direction, the page on taking two doses of Mounjaro covers that scenario in detail.
This is the decision the reader is actually facing. Not whether to physically split the pen, but what to do when the prescribed amount feels like more than they can handle. The options, through the proper clinical route, include: staying at the current dose for additional weeks before titrating upward; managing side effects with hydration, smaller meals and timing the injection strategically; or, in some cases, a prescriber deciding that a lower licensed strength is more appropriate at this stage.
None of those options involve altering what the pen delivers. They all involve a conversation. Our clinical team hears this concern regularly, it is one of the most common questions in the weeks after starting or increasing a dose. A brief message through aftercare gets you a considered answer the same day, not a guess.
It is also worth knowing that concerns about cost sometimes sit behind the question, the idea being that stretching a pen further would make it go twice as far. The Mounjaro cost page explains what you are actually paying for and why the pen's value is in its clinical accuracy, not its volume.
If a current dose is genuinely not tolerable, contact your prescriber before your next scheduled injection. Do not skip it without guidance, and do not attempt to adjust the pen. Your prescriber can advise whether to delay, stay at the current strength, or make another change, all of which are legitimate clinical decisions documented in your care record.
If you experience severe or persistent vomiting, significant abdominal pain, or signs of dehydration alongside your symptoms, seek medical attention rather than waiting for a scheduled review. The MHRA's Yellow Card scheme also allows patients to report unexpected side effects directly, which contributes to ongoing safety monitoring of tirzepatide in the UK.
For everything else, if you are asking whether you can take two 2.5mg doses of Mounjaro, or have questions about your specific dose, whether a switch in injection timing might help, or how to read the pen correctly, the Mounjaro FAQs cover a range of practical scenarios, and the support team is available seven days a week. A related question we see regularly is whether taking two doses of 2.5mg Mounjaro is appropriate, and that page sets out the clinical position clearly. If you haven't yet started treatment and are weighing up your options, speaking to our prescribers is the right first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.